Asset
ZIPALERTINIB
Cullinan Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04036682 | phase1_2 | active_not_recruiting | 2019-10-31 | 2025-10-13 | Cullinan Therapeutics Inc. | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer |
FDA applications (0)
This company has no applications containing this asset.